MCID: NRG005
MIFTS: 27

Neurogenic Hypertension malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Hypertension

About this section

Aliases & Descriptions for Neurogenic Hypertension:

Name: Neurogenic Hypertension 48 68

Classifications:



Summaries for Neurogenic Hypertension

About this section
MalaCards based summary: Neurogenic Hypertension is related to neuronitis and neutropenia monocytopenia deafness. An important gene associated with Neurogenic Hypertension is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. Affiliated tissues include brain, medulla oblongata and kidney.

Related Diseases for Neurogenic Hypertension

About this section

Diseases related to Neurogenic Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
idRelated DiseaseScoreTop Affiliating Genes
1neuronitis9.8
2neutropenia monocytopenia deafness9.8ACE2, ENPEP
3cervicitis9.8
4obesity9.7
5cerebritis9.7
6atherosclerosis9.5
7sleep apnea9.5
8obstructive sleep apnea9.5
9renal hypertension9.5
10cerebral atherosclerosis9.5
11porphyria9.5
12thyroiditis9.5
13hypoxia9.5
14syncope9.5

Graphical network of diseases related to Neurogenic Hypertension:



Diseases related to neurogenic hypertension

Symptoms & Phenotypes for Neurogenic Hypertension

About this section

Drugs & Therapeutics for Neurogenic Hypertension

About this section

Drugs for Neurogenic Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Anti-Infective AgentsPhase 3, Phase 1, Phase 222062
2Antibiotics, AntitubercularPhase 37180
3Anti-Bacterial AgentsPhase 3, Phase 1, Phase 211226
4carnitineNutraceuticalPhase 3162
5Omega 3 Fatty AcidNutraceuticalPhase 31018
6
FesoterodineapprovedPhase 260286930-02-7, 286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Toviaz
7
Minocyclineapproved, investigationalPhase 1, Phase 223110118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline HCl
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
NCGC00178854-01
NSC 141993
NSC141993
Novo-Minocycline
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
8Cholinergic AntagonistsPhase 21706
9Neurotransmitter AgentsPhase 2, Early Phase 118340
10Cholinergic AgentsPhase 23992
11Muscarinic AntagonistsPhase 21166
12
Yohimbineapproved, vet_approvedEarly Phase 128146-48-58969
Synonyms:
(+)-Yohimbin
(+)-Yohimbine
(+)-yohimbine
(16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester
146-48-5
17-Hydroxy-yohimbane-16-carboxylic acid methyl ester
17-Hydroxyyohimban-16-carboxylic acid methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylic acid methyl ester
17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester
2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
4-25-00-01237 (Beilstein Handbook Reference)
65-19-0
AC1L1S1D
APHRODINE
Actibine
Aphrodine
Aphrodyne
Aphrosol
BCBcMAP01_000032
BPBio1_000472
BRD-K35586044-001-02-6
BRD-K35586044-003-03-0
BRN 0097276
BSPBio_000428
BSPBio_001236
Baron-X
Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.
Bio1_000455
Bio1_000944
Bio1_001433
Bio2_000458
Bio2_000938
C09256
CHEBI:10093
CHEMBL15245
CID8969
Corynine
D08685
DB01392
Dayto himbin
EINECS 205-672-0
HMS1362N17
HMS1792N17
HMS1990N17
HMS2089G19
I14-13374
IDI1_002213
 
InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s
Johimbin
KBio2_000576
KBio2_003144
KBio2_005712
KBio3_001031
KBio3_001032
KBioGR_000576
KBioSS_000576
LS-162738
Lopac0_001210
MLS000728591
MLS001333983
MolPort-001-794-653
NCGC00025018-05
NCGC00025018-06
NCGC00025018-07
NSC19509
Prestwick0_000584
Prestwick1_000584
Prestwick2_000584
Prestwick3_000584
Quebrachin
Quebrachine
SMP1_000320
SMR000058527
SMR000470778
SPBio_002647
STOCK1N-51304
Thybine
UNII-2Y49VWD90Q
Yocon
Yohimar
Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester
Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester
Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI)
Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI)
Yohimbic acid methyl ester
Yohimbin
Yohimbine
Yohimbine (DCF)
Yohimbol-16alpha-carboxylic acid, methyl ester (6CI)
Yohimex
Yoman
Yovital
methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate
methyl 17alpha-hydroxyyohimban-16alpha-carboxylate
nchembio.188-comp13
nchembio705-2
trans-Quinolizidine yohimbine
13
Melatoninapproved, nutraceutical, vet_approvedEarly Phase 126873-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
14MydriaticsEarly Phase 1811
15Protective AgentsEarly Phase 17443
16Central Nervous System DepressantsEarly Phase 113403
17Peripheral Nervous System AgentsEarly Phase 123689
18Adrenergic AgentsEarly Phase 15352
19Adrenergic alpha-AntagonistsEarly Phase 1739
20Adrenergic AntagonistsEarly Phase 11573
21Antihypertensive AgentsEarly Phase 14207
22Autonomic AgentsEarly Phase 110150
23AntioxidantsEarly Phase 13050
24YohimbeNutraceuticalEarly Phase 128

Interventional clinical trials:

idNameStatusNCT IDPhase
1Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in ChildrenUnknown statusNCT02192580Phase 3
2L-carnitine on the Prevention of Renal Scarring in Acute PyelonephritisUnknown statusNCT02007889Phase 3
3Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsRecruitingNCT02133885Phase 1, Phase 2
4Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)RecruitingNCT02676154Phase 2
5Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsRecruitingNCT02133872Phase 1
6Study 3: Minocycline Decreases Microglia ActivationNot yet recruitingNCT02213575Phase 1
7Adolescent Blood Pressure Variation and Ventricular MassCompletedNCT00005200
8Brain fMRT In Takotsubo CardiomyopathyRecruitingNCT02240056
9Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic HypotensionNot yet recruitingNCT02963181Early Phase 1

Search NIH Clinical Center for Neurogenic Hypertension

Genetic Tests for Neurogenic Hypertension

About this section

Anatomical Context for Neurogenic Hypertension

About this section

MalaCards organs/tissues related to Neurogenic Hypertension:

36
Brain, Medulla oblongata, Kidney, Heart, Hypothalamus, Pons, Thyroid

Publications for Neurogenic Hypertension

About this section

Articles related to Neurogenic Hypertension:

(show top 50)    (show all 138)
idTitleAuthorsYear
1
Putative Mechanism of Salt-Dependent Neurogenic Hypertension: Cell-Autonomous Activation of Organum Vasculosum Laminae Terminalis Neurons by Hypernatremia. (27895191)
2017
2
Contribution of Orexin to the Neurogenic Hypertension in BPH/2J Mice. (26975709)
2016
3
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. (27754127)
2016
4
Furosemide modifies heart hypertrophy and glycosaminoglycan myocardium content in a rat model of neurogenic hypertension. (27221775)
2016
5
OS 25-02 ORIGIN OF NEUROGENIC HYPERTENSION AND THE SYMPATHO-EXCITATION IN DIET INDUCED OBESITY. (27643054)
2016
6
Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension. (27754863)
2016
7
Carotid body over activity induces respiratory neurone channelopathy contributing to neurogenic hypertension. (25900825)
2015
8
Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. (25489058)
2015
9
I+-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. (26254330)
2015
10
In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope. (26834545)
2015
11
Presympathetic neuron dysfunction--time to reconsider increased intrinsic activity as the cause of neurogenic hypertension. (24987020)
2014
12
Different impacts of I+- and I^-blockers in neurogenic hypertension produced by brainstem lesions in rat. (24614323)
2014
13
Specific respiratory neuron types have increased excitability that drive presympathetic neurones in neurogenic hypertension. (24688126)
2014
14
Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice. (24275840)
2013
15
Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. (22746319)
2013
16
Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model. (23747290)
2013
17
The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. (24002774)
2013
18
Stabilization of hypoxia inducible factor-1I+ ameliorates acute renal neurogenic hypertension. (24309492)
2013
19
Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. (24014829)
2013
20
Chiari I malformation with neurogenic hypertension: case report. (22890471)
2012
21
Neurogenic hypertension and elevated vertebrobasilar arterial resistance: is there a causative link? (22562144)
2012
22
Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. (22958438)
2012
23
Neurogenic hypertension: revelations from genome-wide gene expression profiling. (22639016)
2012
24
Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. (21755262)
2011
25
Coupling between respiratory and sympathetic activities as a novel mechanism underpinning neurogenic hypertension. (21445721)
2011
26
Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension. (21487032)
2011
27
Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. (21536990)
2011
28
Contributions of vascular inflammation in the brainstem for neurogenic hypertension. (21601658)
2011
29
Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. (19923158)
2010
30
Brain microglial cytokines in neurogenic hypertension. (20547972)
2010
31
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. (19926873)
2010
32
Neurogenic hypertension. (20407134)
2010
33
Inflammation and neurogenic hypertension: a new role for the circumventricular organs? (20651292)
2010
34
Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The kidney is not always the target in neurogenic hypertension. (21188820)
2010
35
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. (19762685)
2009
36
Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species: new targets for neurogenic hypertension? (19114641)
2009
37
Do changes in the coupling between respiratory and sympathetic activities contribute to neurogenic hypertension? (19413588)
2009
38
Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. (19047792)
2009
39
Is neurogenic hypertension related to vascular inflammation of the brainstem? (18585782)
2009
40
Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. (19114648)
2009
41
Specific inflammatory condition in nucleus tractus solitarii of the SHR: novel insight for neurogenic hypertension? (18722165)
2008
42
Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. (18443753)
2008
43
Aminopeptidase A: could it be a novel target for neurogenic hypertension? (18362227)
2008
44
Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. (17122386)
2007
45
Neurovascular compression of the medulla: can it cause neurogenic hypertension? (17215662)
2007
46
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. (17519130)
2007
47
Compression of the rostral ventrolateral medulla by a vagal schwannoma of the cerebellomedullary cistern presenting with refractory neurogenic hypertension: case report. (16723872)
2006
48
Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. (16716903)
2006
49
Role of calcitonin gene-related peptide in the phenol-induced neurogenic hypertension in rats. (15120475)
2004
50
Neurogenic hypertension: is the enigma of its origin near the solution? (14676221)
2004

Variations for Neurogenic Hypertension

About this section

Expression for genes affiliated with Neurogenic Hypertension

About this section
Search GEO for disease gene expression data for Neurogenic Hypertension.

Pathways for genes affiliated with Neurogenic Hypertension

About this section

GO Terms for genes affiliated with Neurogenic Hypertension

About this section

Biological processes related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1angiotensin catabolic process in bloodGO:00020059.8ACE2, ENPEP
2angiotensin maturationGO:00020039.8ACE2, ENPEP
3proteolysisGO:00065089.3ACE2, ENPEP
4regulation of systemic arterial blood pressure by renin-angiotensinGO:00030819.1ACE2, ENPEP

Molecular functions related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1metallopeptidase activityGO:00082379.9ACE2, ENPEP
2peptidase activityGO:00082339.8ACE2, ENPEP
3zinc ion bindingGO:00082709.1ACE2, ENPEP

Sources for Neurogenic Hypertension

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet